COST CA23156

Principal Investigator: Tangui Maurice

Principal Investigator (SK): Michal Cagalinec
Participating as Secondary Proposer

Duration: 2024 – 2028
Coordinating Organization: Mécanismes moléculaires dans les démences neurodégénératives (MMDN), Institut national de la Sante et de la Recherche Medicale INSERM, Montpellier, France
Coordinating Organization (SK): Institute of Experimental Endocrinology BRC SAS

Annotation:

The sigma-1 receptor (S1R) is a ligand-regulated endoplasmic reticulum chaperone protein and a target for innovative compounds for the treatment of neurodegenerative and inflammatory diseases, cancers and pain diseases. The SIGMA-1 EUROPE network will bring together disciplines and expertises across Europe to advance the exploration and identification of the role of the Sigma-1 receptor in physiology and pathologies, to design innovative S1R ligands for cellular biology and medicine, and ultimately to train young reserachers and innovators to revise our views of the diseases, to think out-of-the-box and explore novel and innovative therapeutic opportunities.

Keywords:

Pharmacology, Drug development, Translational training, Cytoprotection, Pain

Objectives:

1. Drug design, modelling, radiotracers
2. S1R in neurodegenerative, inflammatory, cancer and cardiometabolic diseases
3. Establishment of SOPs for in vitro and in vivo models to assess S1R ligands
4. Industry strategies requirement for drug development
5. Dissemination, Communication and Outreach

Publications: